QiDe Pharmaceutical Technology

Qide Pharma is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, specializing in the development of next-generation antibody-drug conjugates (ADCs). The company utilizes its proprietary ligase-dependent conjugation (iLDC) platform and intelligent continuous bioprocessing (iCBP) technology to create site-specific, homogeneous ADCs with improved stability and therapeutic windows. Its lead candidate, GQ1001, is a HER2-targeting ADC currently in Phase 2 clinical trials for various solid tumors. Qide Pharma's pipeline also includes candidates targeting TROP2, Claudin 18.2, and other validated oncology targets. The company aims to address unmet medical needs in oncology through innovative bioconjugation chemistry and streamlined manufacturing processes.